Patient characteristics by race and ethnicity
| . | Hispanic (n = 45) . | Non-Hispanic Black (n = 52) . | Non-Hispanic White (n = 398) . | . |
|---|---|---|---|---|
| Patient characteristics . | Median (IQR) or n (%) . | Median (IQR) or n (%) . | Median (IQR) or n (%) . | P . |
| Age at MM diagnosis | 53.3 (48.0, 64.4) | 56.8 (49.7, 62.6) | 62.7 (54.7, 69.1) | <.001 |
| Year of MM diagnosis | ||||
| <2010 | 6 (13) | 15 (29) | 71 (18) | .04 |
| 2010-2014 | 20 (44) | 28 (54) | 182 (46) | |
| ≥2015 | 19 (42) | 9 (17) | 145 (36) | |
| Sex | .02 | |||
| Male | 23 (51) | 22 (42) | 244 (61) | |
| Female | 22 (49) | 30 (58) | 154 (39) | |
| ISS at MM diagnosis | >.9 | |||
| I | 20 (50) | 17 (44) | 153 (44) | |
| II | 10 (25) | 13 (33) | 100 (29) | |
| III | 10 (25) | 9 (23) | 92 (27) | |
| Unknown | 5 | 13 | 53 | |
| CH status | .8 | |||
| No CH | 40 (89) | 47 (90) | 347 (87) | |
| CH | 5 (11) | 5 (10) | 51 (13) | |
| Frontline treatment* | .2 | |||
| PI + IMIDs | 18 (40) | 15 (29) | 164 (41) | |
| PI | 19 (42) | 21 (40) | 125 (31) | |
| IMIDs | 6 (13) | 11 (21) | 90 (23) | |
| Others | 2 (4) | 5 (10) | 19 (5) | |
| Time to frontline treatment (days) | 30 (11, 58) | 27 (14, 69) | 27 (13, 62) | .9 |
| HCT | .8 | |||
| HCT | 29 (64) | 30 (58) | 238 (60) | |
| No HCT | 16 (36) | 22 (42) | 160 (40) | |
| Time to HCT (days) | 270 (189, 462) | 376 (234, 823) | 248 (189, 377) | .01 |
| . | Hispanic (n = 45) . | Non-Hispanic Black (n = 52) . | Non-Hispanic White (n = 398) . | . |
|---|---|---|---|---|
| Patient characteristics . | Median (IQR) or n (%) . | Median (IQR) or n (%) . | Median (IQR) or n (%) . | P . |
| Age at MM diagnosis | 53.3 (48.0, 64.4) | 56.8 (49.7, 62.6) | 62.7 (54.7, 69.1) | <.001 |
| Year of MM diagnosis | ||||
| <2010 | 6 (13) | 15 (29) | 71 (18) | .04 |
| 2010-2014 | 20 (44) | 28 (54) | 182 (46) | |
| ≥2015 | 19 (42) | 9 (17) | 145 (36) | |
| Sex | .02 | |||
| Male | 23 (51) | 22 (42) | 244 (61) | |
| Female | 22 (49) | 30 (58) | 154 (39) | |
| ISS at MM diagnosis | >.9 | |||
| I | 20 (50) | 17 (44) | 153 (44) | |
| II | 10 (25) | 13 (33) | 100 (29) | |
| III | 10 (25) | 9 (23) | 92 (27) | |
| Unknown | 5 | 13 | 53 | |
| CH status | .8 | |||
| No CH | 40 (89) | 47 (90) | 347 (87) | |
| CH | 5 (11) | 5 (10) | 51 (13) | |
| Frontline treatment* | .2 | |||
| PI + IMIDs | 18 (40) | 15 (29) | 164 (41) | |
| PI | 19 (42) | 21 (40) | 125 (31) | |
| IMIDs | 6 (13) | 11 (21) | 90 (23) | |
| Others | 2 (4) | 5 (10) | 19 (5) | |
| Time to frontline treatment (days) | 30 (11, 58) | 27 (14, 69) | 27 (13, 62) | .9 |
| HCT | .8 | |||
| HCT | 29 (64) | 30 (58) | 238 (60) | |
| No HCT | 16 (36) | 22 (42) | 160 (40) | |
| Time to HCT (days) | 270 (189, 462) | 376 (234, 823) | 248 (189, 377) | .01 |
IQR, interquartile range.
For the majority of these regimens, patients were also given dexamethasone. Single-agent PIs and IMIDs were used rarely (<5%).